Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948320 | 0.84 | EGLN1 (0.32) | — | |
| SCHEMBL23947976 | 0.84 | PRMT5 (0.36) | PRMT5WDR77PLATCYP11B1CYP11B2 | |
| SCHEMBL23948294 | 0.84 | CYP11B1 (0.38) | PRMT5WDR77PLATABL1BCR | |
| SCHEMBL23948322 | 0.82 | MELK (0.40) | PLAT | |
| SCHEMBL23948328 | 0.81 | ABL1 (0.38) | PLATABL1BCRCYP11B1CYP11B2 | |
| SCHEMBL23947980 | 0.81 | HCAR1 (0.35) | PLAT | |
| SCHEMBL23948323 | 0.80 | MAPK1 (0.38) | PRMT5WDR77 | |
| SCHEMBL23948455 | 0.79 | MELK (0.43) | — | |
| SCHEMBL23948325 | 0.78 | FLT3 (0.34) | ABL1 | |
| SCHEMBL23947973 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2021211882-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | LTK, FRK, LCK | PRMT5 985/4885WDR77 3365/4885KDM4C 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.